Deep Genomics is a clinical-stage AI drug discovery company that uses its proprietary BigRNA biological foundation model platform to decode RNA biology and identify novel genetic targets and therapeutic candidates that would be impossible to find through traditional methods. Its key features include the AI Workbench, a suite of predictive systems that has made billions of predictions across the entire human genome for millions of genetic variants and hundreds of millions of novel compounds, along with lab-in-the-loop workflows, high-throughput screening technologies, and fit-for-purpose training datasets. It is designed for pharmaceutical and biopharmaceutical partners rather than individual clinicians or small labs, operating through strategic pharma collaborations and an internal pipeline of RNA therapeutic programs targeting rare and complex genetic diseases. Pricing is not publicly listed; the company generates revenue through pharma partnership agreements, milestone-based deal structures, and licensing arrangements rather than a standard software subscription, and has raised $241 million in total funding.
Leave a Reply